Ginkgo Bioworks Holdings, Inc. (DNA)

Ginkgo Bioworks Holdings, Inc. is a pioneering biotech company founded in 2008 by a group of MIT scientists, including CEO Jason Kelly. The company is based in Boston, Massachusetts, and focuses on using advanced technology to program cells, essentially leveraging biology to manufacture a variety of products across numerous industries. Ginkgo's platform enables the design and growth of custom organisms with applications ranging from pharmaceuticals and agriculture to industrial chemicals and more. Notably, the company has taken a significant role in the bioengineering sector with its innovative approach to synthetic biology. In 2021, Ginkgo went public via a SPAC merger, highlighting its growth trajectory and market influence. With an emphasis on sustainability and harnessing the power of biology, Ginkgo Bioworks aims to revolutionize how we create products and address complex global challenges.